Renew Biotechnologies, a US-based biotech company, announced on Thursday that it has named Steven Abbott as its new chief operating officer (COO).

In the new role, Abbott is to lead Wasatch BioLabs, a core Renew Biotechnologies subsidiary, from its present research and development phase into full-scale commercial operations.

Abbott has more than 15 years of experience in the biotechnology and life sciences industries. He has most recently served as vice president of Lab Operations at Flagship Biosciences, Inc. He has served in leadership positions at Q² Solutions, including director of Genomics Business Development and director of Global Genomics Lab Operations.

Chad Pollard, Renew Biotechnologies co-founder and CEO, said, 'We are excited to have Steven Abbott join our executive team at this pivotal point in our development. We are building a 20,000 sqft high-throughput clinical laboratory at Wasatch Biolabs to transition to full-scale clinical services. Steven's molecular diagnostics expertise and operational experience will be crucial in this shift. We are confident his leadership will drive the successful development and launch of our innovative sequencing-based diagnostic tools.'